Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way
Executive Summary
Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.
You may also be interested in...
Part D Overhaul: The Silver Lining Amid Very Dark Cloud Of US Drug Pricing Bill
Senate version of a potential drug pricing overhaul in the US includes one silver lining for manufacturers: a re-design and update of the Part D drug benefit. Is there any chance of extracting that item for the very dark clouds around it?
US Medicare Part D Inflation Is Real, MedPAC Rebate Data Show
The US Medicare Payment Advisory Commission shares its first looks at the impact of rebates in the Medicare Part D program. Rebates do indeed distort the overall spending trends, the analyses suggest – but underlying prices are still increasing relatively quickly.
Medicare Price Inflation Rebates In Build Back Better Bill Are Prospective Only
The legislation would also establish new manufacturer discounts in Medicare Part D as part of a redesign of the benefit that includes a cap on beneficiary out-of-pocket spending. Negotiations are still fluid on the overall legislative package, however, and things could change.